Mustang Bio, Inc. (MBIO) Stock Score, Valuation & Financial Research

Mustang Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MBIO

Mustang Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.46. These figures are a research snapshot, not a buy or sell recommendation.

What Mustang Bio, Inc. does

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Mustang Bio is a clinical-stage biopharmaceutical company that acquires rights to medical technologies through licensing or ownership interests. It funds the research and development of these product candidates with the goal of eventually out-licensing them or bringing them to market.

Products and services

  • The company is developing a pipeline of cell therapies, specifically CAR T therapies for solid tumors, including MB-101 and the combination therapy MB-109.

Business relationships and partnerships

  • City of Hope National Medical Center — A research institution partner for the development of CAR T therapy MB-101 and the combination therapy MB-109. Source
  • Nationwide Children's Hospital — A research institution partner for the development of the HSV-1 oncolytic virus MB-108. Source
  • University of Alabama at Birmingham — A research institution that sponsored a Phase 1 clinical trial for MB-108. Source

Business strengths to evaluate

  • Exclusive licenses from world-class research institutions Source

Business risks and research considerations

  • Clinical-stage development risks and reliance on third-party research institutions Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MBIO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.46
Market capitalization:
3.49M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -3.03M
Free cash flow:
USD -5.26M
Cash:
USD 15.15M
Total debt:
USD 0.00
EPS:
USD -0.45

What stands out

  • Free cash flow is USD -5.26M, negative for the stored period.
  • The balance sheet shows USD 15.15M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 15.15M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MBIO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MBIO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MBIO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MBIO to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of MBIO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MBIO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.